• Anlotinib in Intra-Abdominal Desmoplastic Small Round Cell T

  2026-06-19

  This case report documents the first successful use of the multi-target tyrosine kinase inhibitor anlotinib in treating metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT). The findings suggest anlotinib may represent a promising option for this aggressive and poorly treatable malignancy, with manageable toxicity and significant anti-tumor activity.

• PP2A-Mediated Autophagy Drives C. albicans Biofilm Resistanc

  2026-06-19

  This study reveals that protein phosphatase 2A (PP2A) modulates drug resistance in Candida albicans biofilms through induction of autophagy, specifically via ATG protein phosphorylation. These findings highlight autophagy as a promising regulatory target to overcome persistent fungal biofilm resistance.

• Phosphoproteomic Remodeling Under Chronic Cabozantinib in RC

  2026-06-18

  This study systematically dissects how short- and long-term exposure to Cabozantinib (XL184) induces distinct phosphoproteomic and motility adaptations in renal cell carcinoma (RCC) models. The findings reveal that chronic inhibition leads to selective reprogramming of adhesion and stress signaling, providing a systems-level framework for future mechanistic studies on kinase inhibitor adaptation.

• Ceftolozane-Tazobactam in Nosocomial Pneumonia: Structural a

  2026-06-18

  The referenced study evaluates ceftolozane-tazobactam as a novel antimicrobial option for nosocomial pneumonia, highlighting its unique structural adaptations and robust activity against multidrug-resistant Pseudomonas aeruginosa. The findings inform model design for resistance studies and support the refinement of pharmacodynamic protocols in infection research.

• Carfilzomib (PR-171): Applied Workflows for Proteasome Inhib

  2026-06-17

  Carfilzomib (PR-171) empowers researchers to precisely modulate proteasome-mediated proteolysis, unlocking multi-modal cell death pathways pivotal for radiosensitization in cancer models. Discover how the latest evidence and hands-on protocol refinements with APExBIO’s Carfilzomib (PR-171) can accelerate apoptosis, paraptosis, and ferroptosis research with unmatched reliability.

• Chenodeoxycholic Acid: FXR-Driven Workflows for Renal and Me

  2026-06-17

  Chenodeoxycholic Acid (CDCA) is redefining cholesterol metabolism and kidney injury research through precise FXR activation. This advanced guide delivers actionable protocols, troubleshooting tactics, and experimental insights for leveraging CDCA in FXR-KLF11 pathway studies.

• BIRB 796 (Doramapimod): Structural Innovation in p38α MAPK I

  2026-06-16

  Explore how BIRB 796 (Doramapimod) leverages structural allostery to deliver ultra-selective p38α MAPK inhibition. This article uniquely examines conformational control, dual-action kinase targeting, and assay implications, advancing inflammation research strategies.

• Chenodeoxycholic Acid: Unveiling the FXR-KLF11 Axis in Renal

  2026-06-16

  This thought-leadership article explores the mechanistic underpinnings and translational promise of Chenodeoxycholic Acid (CDCA) in modulating the FXR-KLF11 axis, highlighting its role in cholesterol metabolism research and acute kidney injury models. Integrating the latest evidence with actionable protocol guidance, it clarifies how CDCA serves as a strategic tool for researchers navigating the interface of nuclear receptor signaling and metabolic disease.

• miR-196a Promotes Esophageal Cancer via the MYC/TERT/NFκB Ax

  2026-06-15

  This study uncovers how microRNA 196a drives the aggressiveness of esophageal adenocarcinoma by activating a MYC/TERT/NFκB signaling axis. The findings provide mechanistic detail on how miR-196a overexpression promotes epithelial-to-mesenchymal transition and suggest new intervention points for targeting invasive tumor phenotypes.

• Caspase 3/7 Enable Autophagy and DNA Repair in Breast Cancer

  2026-06-15

  Samarasekera et al. reveal that caspase 3 and caspase 7 orchestrate cytoprotective autophagy and DNA damage response in human breast cancer cells under non-lethal stress. These findings shift the paradigm of effector caspases from purely apoptotic mediators to essential stress adaptation regulators, with broad implications for cancer biology and therapeutic targeting.

• MLN4924 HCl Salt: Precision NEDD8-Activating Enzyme Inhibiti

  2026-06-14

  MLN4924 HCl salt is redefining experimental control over the neddylation pathway, enabling robust studies of ubiquitin-mediated processes in cancer biology, necroptosis, and inflammation. With optimized workflows and troubleshooting guidance, researchers can achieve high reproducibility and specificity in cell signaling and protein degradation assays.

• PP2A-Mediated Autophagy Drives Candida albicans Biofilm Resi

  2026-06-13

  This study uncovers how protein phosphatase 2A (PP2A) regulates drug resistance in Candida albicans biofilms by modulating autophagy via ATG protein phosphorylation. The findings illuminate a new mechanism of antifungal resistance and suggest autophagy as a promising therapeutic target in persistent Candida infections.

• Cefepime (BMY-28142): Reliable Solutions for Bacterial Infec

  2026-06-12

  This article explores practical laboratory challenges in bacterial infection model research and demonstrates how Cefepime (BMY-28142) (SKU BA1013) from APExBIO delivers evidence-backed reliability and data integrity. Scenario-driven Q&A blocks address experimental design, reproducibility, and workflow optimization for researchers using Cefepime in cell viability, proliferation, and CNS infection assays.

• Chenodeoxycholic Acid (SKU B1908): Precision in FXR Pathway

  2026-06-12

  This article delivers an evidence-based exploration of how Chenodeoxycholic Acid (SKU B1908) supports reliable outcomes in nuclear receptor signaling, cholesterol metabolism research, and renal injury models. Scenario-driven Q&A blocks address real workflow challenges and illustrate the reagent's practical value for biomedical scientists. Researchers will find concrete guidance on protocol optimization, data interpretation, and vendor selection, all grounded in primary literature and product data.

• AAPH (2,2'-Azobis(2-methylpropionamidine)): Precise In Vitro

  2026-06-11

  AAPH delivers unmatched reproducibility for in vitro oxidative stress modeling, enabling fine-tuned control of peroxyl radical flux in erythrocyte hemolysis and lipid peroxidation assays. See how this robust reagent—trusted by APExBIO—empowers advanced antioxidant screening and ferroptosis research.

16691 records 1/1113 page Next 12345 下5页 Last page